APEX1 and neoplasm: After 3 weeks, CD133+ GBC-SD -shcontrol cell-derived tumors at the subcutaneously implanting location were lager and grew more rapidly than CD133+ GBC-SD-shAPEX1 cell-derived tumors and CD133+ GBC-SD-shJagged1 cells-derived tumors (Figure 6), indicating that knockdown of APEX1 or Jagged1 in CD133+ GBC-SD cells suppressed the tumor growth in vivo.